A significant change has occurred in diabetes treatment with the launch of Awiqli insulin Icodek by the Danish company Novo Nordisk.
New development in diabetes treatment
This drug is positioned as a basal insulin that needs to be administered only once a week. It is the first insulin of this type in the world. Awiqli is developed for patients with both types of diabetes—Type 1 and Type 2.
Benefits for patients
The introduction of this insulin eliminates the need for daily injections. With Awiqli, patients will only need to make 52 injections per year. This can simplify adherence to the treatment regimen and reduce discomfort from frequent injections for patients.